A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase II  to the Nucleus

(2016) P. Ranganathan et al.   CLINICAL CANCER RESEARCH

Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia

(2016) Thomas B. Alexander et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

(2016) Albiruni R. Abdul Razak et al.   JOURNAL OF CLINICAL ONCOLOGY

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells

(2016) J Etchin et al.   LEUKEMIA

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice

(2015) J Etchin et al.   LEUKEMIA

Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein

(2015) Jo Ishizawa et al.   PHARMACOLOGY & THERAPEUTICS

Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation

(2014) A Israyelyan et al.   BONE MARROW TRANSPLANTATION

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents

(2014) Kaushal Parikh et al.   Journal of Hematology & Oncology

Clinical translation of nuclear export inhibitors in cancer

(2014) William T. Senapedis et al.   SEMINARS IN CANCER BIOLOGY

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

(2013) K. Kojima et al.   BLOOD

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

(2012) P. Ranganathan et al.   BLOOD

High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML)

(2011) Sarah M. Larson et al.   LEUKEMIA & LYMPHOMA

Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials

(2010) Lesley A Smith et al.   BMC CANCER

Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia

(2010) Shuichi Miyawaki et al.   LEUKEMIA & LYMPHOMA

Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant

(2010) Lucy A. Godley et al.   LEUKEMIA & LYMPHOMA

Dose Escalation Methods in Phase I Cancer Clinical Trials

(2009) Christophe Le Tourneau et al.   JNCI-Journal of the National Cancer Institute